Dosage forms and methods for enantiomerically enriched or pure bupropion
AssigneeAxsome Therapeutics, Inc.
InventorHerriot Tabuteau
Life of this patent
Estimating the term…
Abstract
This disclosure relates to dosage forms containing an enantiomerically enriched or pure bupropion such as enantiomeric excess of (S)-bupropion, enantiomerically enriched (S)-bupropion, or enantiomerically pure (S)-bupropion and methods of using these dosage forms. These dosage forms may be administered to human beings in a reduced amount as compared to the amount of racemic bupropion that would be administered in the same situation.
Claims22
A method of treating attention deficit/hyperactivity disorder (AD/HD) comprising orally administering an (S)-bupropion that is at least 95% enantiomerically pure to a human being in need thereof, wherein the (S)-bupropion is not deuterium-enriched, wherein about 20 mg to about 100 mg of the (S)-bupropion is orally administered once daily and is therapeutically effective for treating AD/HD, wherein the (S)-bupropion that is at least 95% enantiomerically pure is orally administered in a dosage form that is free of any active pharmaceutical ingredients other than the (S)-bupropion that is at least 95% enantiomerically pure and the accompanying 5% or less (R)-bupropion.
Dependencies are inferred from the claim text.